Robust Pipeline of Investigational Candidates

Modality Key: Small Molecule | Peptide | Antibody | Gene Therapy

Therapeutic Area Key: Psychiatry | Neurology | Endocrinology | Immunology

Study Initiating

- **NBIB-'223 (Frataxin)**
  Friedreich's Ataxia
- **NBIM-'1748 (Undisclosed)**
  Immunology
- **NBI-'737 (Undisclosed)**
  Endocrinology

Phase 1

- **NBI-'569* (M1/M4 Agonist)**
  Alzheimer's Psychosis
- **NBI-'675 (VMAT2 Inhibitor)**
  CNS Indications
- **NBI-'355 (Nav1.2/1.6 Inhibitor)**
  Epilepsy
- **NBIP-'1435 (CRF_1 Antagonist)**
  Classic Congenital Adrenal Hyperplasia
- **NBIP-'2118 (CRF_2 Agonist)**
  Obesity
- **NBIP-'1968 (Triple G Agonist)**
  Obesity
- **NBIM-'1112 (Undisclosed)**
  Immunology
- **NBIM-'1008 (Undisclosed)**
  Immunology

Phase 2

- **direclidine* (M4 Agonist)**
  Bipolar Mania
- **NBI-'570* (M1/M4 Agonist)**
  Schizophrenia
- **NBI-'890 (VMAT2 Inhibitor)**
  Tardive Dyskinesia
- **NBI-'567*± (M1 Preferring Agonist)**
  Alzheimer's Cognition

Phase 3

- **direclidine* (M4 Agonist)**
  Schizophrenia
- **osavampator‖ (AMPA PAM)**
  Major Depressive Disorder

Neurocrine Biosciences has global rights, unless otherwise noted.
Investigational therapies are not approved for use in any country.
*Licensed from Nxera Pharma.
±Nxera Pharma has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.
‖Takeda Pharmaceutical Company Limited has retained rights in Japan.

CRF2 = Corticotropin Releasing Factor 2; TG= Neurocrine Proprietary GIP-GLP-1-Preferring Triple Agonist" ("Light" on Glucagon Activity); CRF1 = Corticotropin Releasing Factor 1; M1 = M1 Muscarinic Receptor; M4 = M4 Muscarinic Receptor; VMAT2 = Vesicular Monoamine Transporter 2; CNS = Central Nervous System; Nav = Sodium Channel; AMPA PAM = alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid Positive Allosteric Modulator

NEUROCRINE® BIOSCIENCES

© 2026 Neurocrine Biosciences, Inc. All Rights Reserved. CP-NBI-US-0449v16 11/2026